MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Operating Income 2011-2026 | PCRX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -73.4 M | 87.7 M | 60 M | 89.9 M | 46.4 M | 10.5 M | 15.9 M | -24.9 M | -32 M | 9.46 M | -5.16 M | -53.3 M | -49.3 M | -39.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 89.9 M | -73.4 M | 3.05 M |
Quarterly Operating Income Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.36 M | 8.5 M | 1.99 M | - | -140 M | 28.2 M | 13.2 M | - | 17.7 M | 39.9 M | -3.09 M | - | 21.3 M | 31.2 M | 17.4 M | - | 31.4 M | 34.8 M | 19.4 M | - | 17.6 M | -7.15 M | 17.1 M | - | 2.41 M | 5.28 M | 1.08 M | - | 4.05 M | 6.54 M | -6.94 M | - | -3.57 M | -15.8 M | -14 M | - | -20.9 M | -6.44 M | -2.25 M | - | 5.11 M | 1.82 M | 3.34 M | -5.16 M | -985 K | -2.84 M | -9.26 M | - | -12.8 M | -12 M | -18.6 M | - | -15.7 M | -6.63 M | -11.1 M | - | -8.73 M | -8.53 M | -7.12 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 39.9 M | -140 M | -73.3 K |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.45 | 0.58 % | $ 86.3 M |  Canada |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.02 | - | $ 110 M | Canada |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 11.77 | 1.99 % | $ 836 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 5.04 | 0.6 % | $ 325 M | USA |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.06 | 0.66 % | $ 43 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
30.5 M | $ 34.91 | 2.38 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.33 | 3.22 % | $ 426 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 0.62 | 2.94 % | $ 10.8 M |  China |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.44 | -4.64 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.58 | -2.27 % | $ 340 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
-1.12 B | $ 9.72 | 4.4 % | $ 1.35 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.4 | -2.24 % | $ 2.98 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 6.18 | 4.57 % | $ 186 M | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.96 | 6.61 % | $ 22.4 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.9 | 4.68 % | $ 44.9 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 2.17 | - | $ 22.7 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 7.48 | 2.33 % | $ 305 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.37 | -0.84 % | $ 320 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.9 | 0.15 % | $ 4.26 B | Canada |
 |
Viatris
VTRS
|
766 M | $ 13.51 | - | $ 16.2 B | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.72 | 1.41 % | $ 3.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |